HRMY
Harmony Biosciences Holdings
39.40$
-1.4%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +21.5% | -59.4% | +36.9% | +65.4% | +7.2% | -55.0% | +133.4% | +37.1% | +16.0% | -78.0% | +233.0% | – | |
| – | -16.7% | +2.9% | -1.2% | -1.4% | -2.8% | +2.8% | -2.7% | +2.7% | +21.3% | -19.7% | +0.0% | – | |
| – | +11.4% | +17.7% | +5.1% | +4.4% | -12.0% | +23.6% | -8.0% | -5.5% | -6.1% | +4.5% | -12.1% | – | |
| – | +368.7% | -156.1% | – | – | -33.7% | -287.0% | – | +137.8% | +130.6% | -167.0% | – | – | |
| – | – | -95.3% | +12,540.0% | -99.5% | +17,000.0% | -75.0% | -96.9% | +1,675.0% | +50.7% | -100.0% | – | – | |
| – | +4,336.0% | -82.8% | +786.8% | – | -1,064.7% | – | -929.3% | -75.6% | +268.2% | +941.5% | -28.4% | – | |
| – | +0.3% | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | – | – | – | -100.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | +33.3% | +0.0% | +0.0% | – | |
| – | -2.9% | -93.2% | -5.2% | -65.9% | +133.3% | -87.2% | +663.1% | +11.5% | +0.6% | +139.4% | -92.3% | – | |
| – | -279.8% | – | -173.6% | – | -6.3% | -45.2% | +58.5% | +76.9% | +4.5% | -254.6% | – | – | |
| – | +21.3% | -59.3% | +34.8% | +67.9% | +6.5% | -54.9% | +134.3% | +37.0% | +16.0% | -78.0% | +233.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.